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multidrug  resistance  is  a  serious  problem  in  current  chemotherapy.  The  efflux  system 
largely responsible for resistance in Escherichia coli contains the drug transporter, AcrB. The 
structures of AcrB were solved in 2002 as the symmetric homo-trimer, and then in 2006 as 
the asymmetric homo-trimer. The latter suggested a functionally rotating mechanism. Here, 
by molecular simulations of the AcrB porter domain, we uncovered allosteric coupling and 
the drug export mechanism in the AcrB trimer. Allosteric coupling stabilized the asymmetric 
structure with one drug molecule bound, which validated the modelling. Drug dissociation 
caused a conformational change and stabilized the symmetric structure, providing a unified 
view of the structures reported in 2002 and 2006. A dynamic study suggested that, among the 
three potential driving processes, only protonation of the drug-bound protomer can drive the 
functional rotation and simultaneously export the drug. 
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M
ultidrug resistance during infection and cancer treatment 
is a serious problem1,2. It is often caused by the overex-
pression of efflux transporters that pump drugs out. In 
E. coli, among many such transporters, the tripartite efflux system, 
AcrB–AcrA–TolC, is largely responsible for resistance against many 
lipophilic antibiotics3–9. The tripartite system spans the inner and 
the outer membranes of the cell, effectively transporting drugs from 
the cell to the medium, bypassing the periplasm10,11: TolC is a generic 
outer membrane channel in which drugs can passively move12, AcrB, 
a member of resistance-nodulation-cell division transporters, is the 
inner membrane transporter that pumps drugs from the cell to the 
TolC channel driven by the proton-motive force13–16, and AcrA is an 
adaptor that links AcrB and TolC11,17. Thus, the active pump in this 
tripartite system is primarily realized by AcrB. Moreover, AcrB is 
currently one of the best-characterized transporters, making it an 
ideal target for simulation study.
For AcrB, the high-resolution structure was first solved in 200213. 
The structure clarified that AcrB is a homo-trimer assembled in a tri-
angular-prism shape and each protomer comprises three domains, 
trans-membrane (TM) domain, porter domain and TolC docking 
domain (see Fig. 1a). The TM domain must be responsible for the 
proton transfer across the inner membrane harvesting the driving 
energy. The porter domain is made of four subdomains, PN1, PN2, 
PC1 and PC2, and is responsible for the drug binding. TolC dock-
ing domain has a funnel-like shape with a central channel that con-
nects to TolC. Notably, the structure was solved in the crystal with 
the threefold crystallographic symmetry (R32 space group). Thus 
the asymmetric unit contained only one protomer, which enforced 
the reconstructed trimer structure being symmetric. It was not clear 
whether the perfect symmetry is the intrinsic property of the mol-
ecules or, to some extent, the artefact of the crystal packing.
This concern motivated crystallographers to solve the AcrB 
structure in a crystal that lacks the threefold symmetry, leading 
to the asymmetric trimer structures reported in 2006 and 2007 
by three groups14–16. Interestingly, these new structures solved in 
different crystallographic symmetries were essentially identical 
to each other. In the new structure, albeit its overall similarity 
to the structure solved in 2002, the three protomers took some-
what different conformations, which may represent three particu-
lar stages during one functional cycle. Specifically, in the porter 
domain, one protomer (protomer I) took the ‘binding’ (denoted 
as B) conformation, where a drug molecule (for example, mino-
cycline) was bound in a pocket formed by the three subdomains, 
PN1, PN2 and PC1 (blue chain in Fig. 1b). Moreover, the B con-
formation has an evident open entrance, and thus is essentially 
the inward-facing state18. In the second protomer (protomer II), 
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Figure 1 | The crystal structure and coarse-grained (CG) model of AcrB. (a) side view of the crystal structure of AcrB; the drug molecule is represented 
by van der Waals’ spheres. (b) Isolated porter domain viewed from the cell exterior. The protomers in blue, red and green represent the binding 
(abbreviated by B), extrusion (E) and access (A) states respectively. (c) Trans-membrane domain viewed from the cell exterior. The key residues 
around protonation sites are represented by sticks. (d) The CG model of the AcrB porter domain and the drug, minocycline (yellow). Two residues that 
hide the drug are not drawn. The chains being the B, E and A states in the crystal structure are numbered by I, II and III respectively. (e) A trajectory 
of conformational changes of the single protomer. The three Q scores (see methods) are plotted simultaneously, where the dashed line indicates the 
start for production. Representative snapshots for the three states are also shown above the time series, in which the red and pink spheres indicate key 
conformational difference. (f) Results for the single protomer simulation with the control set. The values near circles are the probabilities of corresponding 
states, whereas those beside arrows are transition frequencies between states.ARTICLE     
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called ‘extrusion’ (E) conformation, one sees the exit path con-
nected from the binding pocket to the central pore that is linked 
to the TolC channel, whereas the entrance gate is closed and the 
binding pocket is shrunk (red chain in Fig. 1b). Thus, this is an 
outward-facing conformation. The third protomer (protomer III) 
took the ‘access’ (A) conformation, which resembles the B confor-
mation except that the binding pocket is shrunk so that no drug 
molecule  can  be  accommodated.  This  looks  an  inward-facing 
state to incorporate the drug (green chain in Fig. 1b). The A con-
formation is very close to the structure solved in 2002 (Cα root 
mean square deviation is 1.2 Å). The conformational difference 
among protomers is not only in the porter domain, but also in the 
TM domain which is crucial for the proton transport mechanism; 
D407 and/or D408 in the TM domain is likely to be protonated 
only in the E form, but not in the A or B form (Fig. 1c).
The asymmetric structure of AcrB immediately led to the pro-
posal of the functionally rotating mechanism14–16, by analogy to 
the binding change mechanism for ATP synthase19. Namely, start-
ing from the BEA state (that is, the asymmetric crystal structure. 
Here, the first, second and third characters indicate the states of 
protomers in a counterclockwise order, for example, the protomers 
I, II and III respectively), after one functional step, the protomer 
I changes its state from B to E, the protomer II from E to A and 
the protomer III from A to B, in a coordinated way. As a trimer, 
this coordinated change results in the EAB state and thus can be 
viewed as the 120° rotation of the functional state when viewed 
from the outside. In three such steps, each protomer changes its 
state in a cyclic way, B→E→A→B, which may export one drug 
molecule per protomer. Although recent in vivo experiments indi-
rectly  supported  this  functionally  rotating  mechanism20–22,  the 
difficulty in in vitro experiments precludes the more direct proof. 
Given this situation, molecular dynamics (MD) simulations may 
provide some further supports of the model, which is the purpose 
of this article.
Although the MD simulations can be a powerful approach to 
provide  high  spatio-temporal  resolution  insights  to  transporter 
functions, the time scale reachable by the conventional all-atom 
MD is far below the time scale relevant to the AcrB functional cycle. 
Thus, some accelerations are often used, for example, the targeted-
MD implemented in a recent study of AcrB, by which interesting 
drug translocation, but not the complete export, was observed23. 
Instead, here, we used a structure-based coarse-grained (CG) model 
recently developed based on the energy landscape perspective24–26, 
making much more comprehensive simulation possible. In particu-
lar, we represented each residue in the protein as a bead and used 
the multiple-basin model25,27,28.
Here, using computational modelling, we address both the ther-
modynamics and the dynamics of the porter domain of AcrB. In 
the thermodynamics, one fundamental question is what caused the 
symmetry breaking. We investigated the relation between the sym-
metric structure solved in 2002 and the asymmetric one solved in 
2006. In the dynamic study, we investigated the structural transition 
pathways: in a functional step from the BEA state, what is the order 
of conformational changes for protomers? In terms of energy, the 
first change is most likely driven by either the E→A (deprotonation) 
or the B→E (protonation). However, the detail is largely unknown 
and so we address this problem here.
Results
Modelling each protomer with the triple-basin CG model. We 
start with the CG modelling of each AcrB protomer, for which the 
asymmetric AcrB structure suggests the presence of at least three 
stable states; the B, E and A states. The prerequisites to the AcrB 
trimer-complex  simulations  are  to  model  the  energy  landscape 
that has the corresponding three basins and to realize simulations 
of  conformational  transitions  between  them.  Given  the  crystal 
structures of the three states, we can easily achieve them by using 
the multiple-basin model25,29.
The multiple-basin model was developed based on the energy 
landscape perspective of proteins30–33. The perspective clarified that 
proteins have evolved their sequences so that the overall energy 
landscapes resemble funnel-like shape enabling the proteins to fold 
to their native states sufficiently quickly. When magnified, the native 
basin often has multiple minima and transitions among them are 
crucial  for  their  functioning.  An  ideal  funnel-shaped  landscape 
with only one native state can concisely be expressed by the topol-
ogy-based model, called the Go model24,34. By smoothly connect-
ing two or more Go models, the multiple-basin model realizes both 
the overall funnel-like shape towards the native basin and multi-
ple minima within the native basin. This model has recently been 
applied to some biomolecular machines25,27,28.
We used the multiple-basin model with triple basins correspond-
ing to the B, E and A states of the AcrB protomer (Supplementary 
Methods). To the best of our knowledge, this is the first realization of 
the triple-basin energy landscape by structure-based methods. Here, 
only the porter domain of AcrB was considered and each amino acid 
in the protein was represented by a sphere centred at the Cα atom 
(Fig. 1d). The drug was not explicitly treated in this and the next sec-
tions, but was included in the study of dynamics and drug export.
In the triple-basin model of each protomer, there are two types 
of essential parameters that crucially affect the dynamics and the 
thermodynamics of the protein. The first parameter is the coupling 
constant ∆ij that controls the barrier height between the states i and 
j. For the two-basin case, the value of ∆ can be inferred from experi-
mental kinetic data35, if available. Here, however, without any prior 
knowledge we set all ∆ij equal (denoted as ∆). The change in ∆ basi-
cally changes the time scale for all the transitions in the same way, 
but does not affect the thermodynamics or relative order of events. 
Thus, we set the value of ∆ only for the computational reason; we 
used a sufficiently large absolute value of ∆ so that transitions among 
the three states are realized within the allowed computer time (Too 
large  absolute  value  of  ∆  is  a  problem,  too.  See  Supplementary 
Methods). The second type of parameters is the energy depths of 
the three basins, ∆VB, ∆VE and ∆V A, which controls the relative sta-
bilities. One of the three parameters can be set as the reference (here 
∆V A = 0), so that the remaining two parameters (∆VB and ∆VE) are 
essential. For them, below we scanned broad range of values.
As a preparation to the trimer-complex simulation described 
later, we sought a parameter set (∆VB, ∆VE ) that results in the three 
states equally probable as a protomer, that is, the three states have 
the same free energy. By performing iterative MD simulations, we 
realized it with (∆VB, ∆VE)  =  ( − 8.6,  − 2.5) (in the energy unit of 
4.17 kBT, where kB is the Boltzmann constant and T the simulation 
temperature). This will be used as the ‘control’ set, later. We note 
that the drug was not explicitly treated here and thus the low ∆VB 
value implicitly took into account some additional stability by the 
drug binding. A typical trajectory with this condition is illustrated 
in Figure 1e. The state of a protomer was quantitatively measured by 
the fraction of formation of certain native contacts (see Methods). 
Figure 1e shows that the simulated protomer travels all the three 
states repeatedly in a single trajectory.
The thermodynamics and the kinetics of the protomer in the ‘con-
trol’ set are summarized in Figure 1f. The populations of the three states 
(the numbers near the circles in Fig. 1f) were indeed almost the same. 
Interestingly, the transition frequencies between the states (the num-
bers near the arrows) are not equal. The transitions between the A and 
the B states are the most frequent, whereas the transitions to and from 
the E state are somewhat slow. Especially the transition between B and 
E states is the slowest. By the choice of the equal coupling constant ∆, 
this reflects the difference in the distances between the conformations. 
The A and B conformations are relatively close, whereas the E state is 
somewhat far from the other two (see Supplementary Table S1).ARTICLE
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Allosteric coupling revealed by a thermodynamic study. We now 
turn to the equilibrium thermodynamics of AcrB trimer where the 
allosteric coupling among the three protomers is crucial. To address 
the allostery, we need a careful computational modelling of the 
inter-protomer interface interactions, and so we took a multiscale 
approach. First, by the standard all-atom energy function, we esti-
mated the inter-protomer interactions at each of the three interfaces, 
that is, the B/E, the E/A and the A/B interfaces, at the asymmetric 
BEA structure. Finding that strengths of contact energies depend on 
their conservation in the three interfaces, we classified the residue 
pairs at the interfaces into three sets (see Supplementary Methods). 
The ‘com3’ set contains the residue pairs that make contacts in all 
three interfaces. These pairs have the strongest interactions. The 
pairs that make contact only at the two interfaces (called the ‘com2’ 
set) have the middle-strength interactions. The pairs that make con-
tacts only at one interface are classified into the ‘spec’ set, which has 
the weakest interactions. For each set, based on the all-atom energy 
estimate, we assigned the CG contact strengths (see Methods and 
Supplementary Table S2).
Combining  these  inter-protomer  interactions  with  the  intra-
protomer  model  of  the  ‘control’  set  (∆VB,  ∆VE) = ( − 8.6,   − 2.5) 
defined  above,  we  simulated  the  AcrB  trimer.  The  equilibrium 
ensemble thus obtained was dominated by the AAA state (~60% in 
population), with some subdominant populations of the BBA and 
the AAB states (Fig. 2b, the top left panel). This was understood 
by the analysis that, over the simulated ensemble, the inter-pro-
tomer average energies at the B/E, the A/E and the E/E interfaces 
are much weaker and thus unfavourable than other interfaces (see 
Supplementary Fig. S1). This is in harmony with the asymmetric 
crystal structure, where the B/E interface is markedly sparse and 
thus is weakly interacting (Fig. 1b). Moreover, the B/B interface 
interaction is also relatively weak.
Starting from the control set, we then altered the relative stabil-
ities (∆VB, ∆VE) in the two dimensions, leading to the ‘phase dia-
gram’ depicted in Figure 2a. Here, the ‘phase’ stands for the most 
probable trimeric state, which is not the rigorous ‘phase’ in clas-
sical thermodynamics. The boundaries between different phases 
are illustrated by lines. For the x and y axes, we used the deviation 
from the control, δB = ∆VB − ∆Vc,B and δE = ∆VE − ∆Vc,E respectively, 
where the subscript ‘c’ means the ‘control’. The phase diagram was 
calculated by the standard histogram re-weighting method (see 
Supplementary Methods).
In the phase diagram (Fig. 2a), we found a triangular region 
in which the BEA state is dominant. Apparently, this corresponds 
to the asymmetric crystal structure. Thus, with the modelled allo-
steric coupling and a certain set of relative stabilities, the asymmet-
ric structure can be a stable form, which validates the modelling. 
The population of the BEA was the largest at (δB, δE) = ( − 0.5,  − 3.5) 
(Fig. 2b, the bottom left panel), which was denoted as ‘optimized’. 
We assume that this optimized value corresponds to the real BEA 
state as the asymmetric BEA state was found experimentally.
Because the BEA state was found with one drug molecule bound 
to the B protomer, we now ask what would happen if the drug is dis-
sociated. Computationally, the drug binding was effectively treated 
by a low ∆VB value, and so the drug dissociation corresponds to 
the increase in δB. The phase diagram indicates that, by increas-
ing δB (moving to the right in the diagram), we almost surely reach 
the AAA phase where the AAA state dominates. Importantly, this 
AAA state is essentially the symmetric trimer structure obtained 
in 2002 because, as noted before, the A form is very close to the 
conformation in the structure solved in 2002. Although the drug 
binding energy is not accurately estimated here, we chose, only for 
illustration, (δB, δE) = (1.0,  − 3.5) as a representative point for the 
drug unbound state (denoted as ‘unbound’; see Fig. 2b, the top right 
panel, for the population). This leads to an important conclusion 
that, if the BEA structure is the stable structure with a drug bound 
to the B conformer, the drug dissociation most likely leads to the 
symmetric AAA structure. Figure 2a suggests that if we start from a 
non-optimal value of (δB, δE) in the BEA region, the dominant drug 
unbound state can be the AAE state. Even in this case, the prob-
ability of the AAA state is competitively high (see Supplementary 
Fig. S2). The conclusion here is also robust with respect to model 
parameters (see Supplementary Fig. S2).
Functional rotation and drug export by the dynamic study. Next, 
we studied the dynamic aspect of the AcrB function. Does the func-
tional rotation really occur? Is the drug molecule transported to the 
outer membrane side? Addressing these questions, we performed a 
series of dynamic simulations of the drug export adding two more 
elements to the previous simulation system. First, we included one 
drug molecule explicitly represented by a CG model. Second, to 
form the natural ‘exit’ tunnel, we added a few more amino acids 
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Figure 2 | Thermodynamics of the porter domain of AcrB. (a) Two-
dimensional phase diagram. The x and y axes measure the variation of 
the stabilities of the B and E states respectively, with the ‘control’ as the 
reference (see text). Different phases are separated by solid lines, and 
the dominant configuration within each phase is indicated. The trimer 
configuration is represented by a triplet of characters, in which the 
first, second and third characters indicate the states of protomers in a 
counterclockwise order, e.g., the protomers I, II and III respectively. The 
phase where ‘BEA’ dominates is emphasized by the thicker green line. 
The three models used in this work, ‘control’, ‘unbound’ and ‘optimized’, 
are indicated by blue squares. The probability of ‘BEA’ on each point is 
expressed by colours. (b) Probabilities of all possible states for the three 
models. ‘Ts’ means the transition state, in which one or more protomers 
stay in none of the three states.ARTICLE     
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belonging to the TolC docking domain (see Methods). More specifi-
cally, we set the initial state as the protomers I, II and III being in 
the B, E and A states, respectively. For the protomer I, the drug was 
explicitly included and thus the unbound δB = 1.0 was used, whereas 
for other protomers, we did not include the explicit drug and thus 
assumed the bound (optimized) δB =  − 0.5.
Assuming that the BEA state is one of the on-pathway functional 
states, we can think of three possibilities to go from the BEA state: 
the next event is activated either by the protomer I probably through 
protonation in the TM domain, by the protomer II probably through 
deprotonation in the TM domain or by the protomer III perhaps 
through the drug binding to the porter domain.
We tested these three scenarios to address which is more likely. To 
mimic the activation by the deprotonation in the protomer II, dur-
ing the simulation from the BEA state, we suddenly decreased the 
∆V A value of the protomer II by 10.0 that induced the conformational 
change of this protomer to the A state (denoted as ‘E→A’ type). The 
same kind of switching was used to mimic the activation in the pro-
tomer I (‘B→E’) and the activation in the protomer III (‘A→B’). For 
each case, after switching, we monitored what happened in the trimer 
state, as well as the drug originally bound in the protomer I.
We start with the case of the activation in the protomer II (the 
E→A type). Figure 3b monitors the drug export (in y axis) and 
the conformational change (in x axis) for 10 independent trajec-
tories. Here, the x axis indicates how many protomers completed 
their  conformational  changes;  zero  means  the  initial  state  and 
three means the complete transition to the EAB state. The y axis is a 
designed coordinate that reports the location of the drug (see Sup-
plementary Methods and Supplementary Fig. S3); around zero at 
the binding pocket, the negative value (up to  − 20) along the ‘cleft’ 
tunnel (see also Fig. 1b) towards the periplasm and the positive 
value (up to 28) towards the TolC-side exit. Thus the positive value 
indicates the functional drug export. In the current simulations, of 
the 10 cases, nine trajectories showed the drug export to the cleft 
direction (see also Supplementary Movie 1). On top, the conforma-
tional change did not complete for all 10 trajectories. The protomer 
I changed from the B to the A state in all cases (Fig. 3e shows one 
example). All these consistently suggested that this is not the likely 
mechanism.
Second,  we  tested  the  scenario  that  the  protonation  in  the 
TM domain of the protomer I drives the change (the B→E type). 
Figure 3a shows that for all 10 trajectories the three protomers 
completed their structural changes successfully and the drug was 
exported to the exit tunnel towards the TolC channel (see also 
Supplementary  Movie  2).  The  results  are  perfectly  compatible 
with  the  functionally  rotating  mechanism  and  simultaneously 
imply that the protonation process on the B conformer drives the 
change of the trimer from the BEA state. In this set of simula-
tions, after the B→E change in the protomer I (see Fig. 3d), the 
next  step  was  the  conformational  changes  either  in  protomer 
II or III. Moreover, of eight trajectories, the drug was exported 
when only one or two protomers changed their conformations to 
the target ones (see Fig. 3a), implying that for a successful drug 
export alone the completion of the overall functional rotation is 
not compulsory. However, the complete conformational changes 
in the trimer are necessary for the next cycle.
The third case, the A→B type, showed that, of the 10 trajectories, 
only one case went right, but of 8 trajectories, the drug was exported 
to the cleft and of nine cases the protomer I changed from the B to 
the A state (Fig. 3c and f). Interestingly, in one exceptional case, the 
protomer I changed from the B to the E state and, simultaneously, 
the drug was exported to the exit.
Discussion
The current thermodynamic study suggested that, given that the 
BEA is the stable state with one drug bound to the B protomer, 
the drug dissociation stabilizes the AAA state. This needs some 
remarks. First, this does not mean the AAA state is the functional 
on-pathway state. In particular, the dynamic study under proper 
driving force (that is, the B→E type) did not show the AAA inter-
mediate. Instead, it suggests that, when the medium has low con-
centration of AcrB ligands, the AcrB trimer falls into the AAA state. 
Biologically, we speculate that, by taking the ‘resting’ AAA state, 
AcrB does not transport the proton and thus can avoid the energy 
leak. Second, some reported crystal structures took asymmetric 
trimer state without bound drug14–16. It was argued that those struc-
tures may not be actually ‘substrate free’, but may bind detergent, a 
known substrate of AcrB36. Indeed, in a recent structure of MexB, 
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Figure 3 | Dynamic simulations for the functional rotation and the drug export of AcrB. Trajectories are distinguished by different colours, and the 
results of ‘B→E’, ‘E→A’ and ‘A→B’ type simulations (see text) are placed, in order, from the left to the right columns. In (a–c), dashed lines represent the 
criteria to determine whether the drug is exported through the ‘exit’ or ‘cleft’. For clarity of the figures, once a trajectory goes across the thresholds,  
its y axis value is frozen whereas x axis value continues to change. (d–f) Ternary plots of the Q scores, which show the itinerancy of the state of protomer I  
(see supplementary methods). only representative trajectories are drawn for clarity.ARTICLE
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a homologue of AcrB, one detergent molecule was identified in the 
binding pocket37.
In the dynamic study, the results suggested strong correlation 
between the conformational change of protomer I and the drug 
export. To understand this correlation, here we use a rather simpli-
fied argument. As in Table 1, each state was characterized by the 
opening (O) or closing (X) of the four gates: ‘entrance’, ‘cleft’, ‘bind-
ing pocket’ and ‘exit’. Suppose that initially protomer I stays in the 
‘B’ state and so both ‘entrance’ and ‘binding pocket’ are open; thus 
the drug is bound in the pocket. When the protomer I is forcibly 
changed from the B to the E state, the entrance, the cleft and the 
binding pocket are all closed, but the exit gate opens, resulting for 
the drug to be exported through the exit. Nevertheless, when other 
protomers are forced to change, in the E→A and the A→B types, 
almost always the protomer I jumps to the A state because the B and 
A states are intrinsically close to each other. This transition to the A 
state in the protomer I implies that both the binding pocket and the 
exit are closed, but the entrance and the cleft remain opened, which 
leads the drug to be exported through the cleft.
These results are consistent with the model recently postulated 
by Pos based on the analogy to the ‘binding change mechanism’ of 
FoF1-ATP synthase38. We map the drug export process of AcrB onto 
the ATP synthesis mode of F1-ATPase. For the latter, the energetic 
bottleneck is the dissociation of ATP, for which the mechanical 
work in the rotation of the central stalk is used. In AcrB, the cur-
rent work showed that the drug dissociation needs to be driven for 
the successful functional rotation. Although it is not a priori sure to 
what extent the analogy to F1-ATPase holds for AcrB, the current 
simulations strongly support the analogy.
Next, we discuss the drug passage routes observed in the simula-
tions. Figures 4a and b illustrate the drug export to the exit tunnel. 
This exit is connected to the TolC channel and thus naturally it is the 
right pathway to go out from the binding pocket to the cell exterior. 
Figures 4c and d show the drug export to the cleft tunnel. This path-
way from the binding pocket to the cleft is very clear in the crystal 
structure. Is this cleft tunnel a potential drug import pathway? We 
note that this cleft tunnel is connected to the periplasm, 15 Å apart 
from the membrane surface. Biologically, AcrB is supposed to grab 
a drug molecule from the inner membrane surface, and for this pur-
pose, the cleft tunnel is not useful. Interestingly, Pos proposed a pos-
sible role for the cleft tunnel (‘tunnel 2’), being as an alternative ‘exit’ 
for the release of non-substrates taken by accident into the binding 
pocket38. Our observations may support this idea.
Once we have the phase diagram (Fig. 2a), deduction to a sim-
pler statistical model as in the reference39 may have some merit. 
Indeed, we could reproduce rough, but not complete, feature of the 
phase diagram by calibrating parameters in the simpler model (see 
Methods and Supplementary Fig. S6).
Finally,  all  the  simulations  here  included  the  porter  domain 
alone. The inter-domain coupling between the TM domain and the 
porter domain in one protomer is of essential importance, too.
Methods
Reference structures. The crystal structure with the PDB entry 2DRD14 was 
adopted as the reference for models of both the protein, AcrB, and the drug, mino-
cycline. In this work, three constructs were used: (1) the single protomer of the 
AcrB porter domain that contains L30-A183, G271-F332, P565-Q726 and E810-
A873; (2) the trimer complex of the AcrB porter domain that contains the same 
residues as 1; (3) the trimer complex of the AcrB porter domain and some capping 
residues and the minocycline. The capping residues, M184-W187, A753-M781 and 
A215′-A236′, belonging to the TolC docking domain participate to the exit tunnel, 
where the prime means the residue belonging to the neighbouring protomer (see 
Supplementary Fig. S4). The symmetric structure with the PDB entry 1IWG13 was 
also considered merely for a comparison with 2DRD. All the structural graphics 
were drawn by PyMOL (http://www.pymol.org).
Coarse-grained model. We briefly summarize the simulation model and the 
details are found in the Supplementary Methods. The protein was simplified by 
using one bead, placed on the position of Cα atom, per one amino acid. For each 
porter domain of the protomer, the multiple-basin model25 with three basins was 
used, where the three fiducial structures correspond to the B, E and A structures 
of 2DRD.
Because the inter-protomer interactions are crucial for the allosteric effect, 
we treated them with much caution. We modelled them using the asymmetric 
AcrB structure, 2DRD, which has the three inter-protomer interfaces: for the pairs 
that are in contacts in all the three interfaces (the com3 set), we used a triple-well 
pairwise potential somewhat similar to used in refs 40, 41. In a similar way, the 
com2 pairs were modelled by a double-well pairwise potential, and the spec pairs 
were modelled by the Lennard-Jones-type potential (see Supplementary Fig. S5). 
To determine the relative depths of the wells for these inter-protomer interactions, 
we estimated the residue–residue pairwise energies of the corresponding pair at 
the asymmetric structure using the all-atom energy function, AMBER (version 10) 
ff99sb force field42,43 with a GB/SA implicit solvent model44,45. We found that the 
com3 pairs, on average, have the strongest attraction, and the spec pairs have the 
weakest attraction, which was used to determine the relative depths of the wells.
The minocycline, drug, was represented by six beads connected by pseudobonds 
between neighbours and placed at the positions of carbon atoms (in a bonded order) 
C21, C20, C17, C8, C13 and C71. The molecule was modelled as essentially rigid. 
Interactions between the drug and AcrB consist of two terms: (1) a generic repulsive 
term for all the pairs, and (2) the hydrophobic attraction similar to that used in ref. 27 
between the drug beads and the residues in the binding pocket of AcrB, A47, Y49, P50, 
L177, F178, Y275, I277, I278, A279, A286, L289, F610, A611, V612, F615 and I626.
Simulation protocols. All the CG simulations were performed by the CafeMol 
package (http://www.cafemol.org). We conducted three sets of simulations: (1) 
for single-protomer simulations, 20 independent trajectories were run, each with 
Start
Exit
I
III
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Cleft
Exit
Cleft
Q657
I658
K659
D660
T714
S715
V716
R717
A661 P718
L578 N719
P579 G720
Q124
Q125
E121
Y49
P50
N760
V759
Y758
S757
Figure 4 | Snapshots of drug export through ‘exit’ and ‘cleft’. The 
snapshots of the drug in an exporting process are superimposed, and 
the odd and even time slices are in yellow and orange respectively. The 
protomer I is drawn transparent. The circle and arrow indicate the starting 
point and the direction of export respectively. (a) The drug was exported 
through ‘exit’. (b) Closed-up view of the ‘exit’; some residues are labelled 
and drawn in red. (c) and (d) show the drug export through the ‘cleft’ and 
the closed-up view of the ‘cleft’ respectively.
Table 1 | Structural characteristics of the three states.
Entrance Cleft Binding  
pocket
Exit
A/access o o X X
B/binding o o o X
E/extrusion X X X o
o, open; X, closed.ARTICLE     
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1.2 × 106 steps for the equilibration and 1.9 × 107 steps for the production. (2) For  
the trimer equilibrium simulations, 100 independent trajectories were run, each 
having 2.0 × 106 steps for the equilibration and 1.9 × 107 steps for the production.  
(3) In the simulation of drug export dynamics, 10 trajectories were run for each 
type of ‘driving force’ (see above). Each trajectory has 2.0 × 105 steps before the 
switching of energy landscape and 6.0 × 106 steps afterwards.
All the CG simulations were carried out in constant temperature with Berend-
sen’s thermostat46 at the temperature T = 0.24 (the Boltzmann constant kB was set to 
1 in the current unit of temperature).
The state of the protomer was monitored by the fraction of formation of certain 
native contacts, called Q score. To monitor the closeness to the E state, for example, 
we used a set of residue pairs that are in contact in the E state, but not in contact in 
the B or the A state. These ‘E-specific’ contacts monitor the closeness to the E state 
(see Supplementary Methods for more details).
Statistical model. A simple statistical model, similar to that used in the previous 
work39, was built to compare with the current CG model. Each protomer takes one 
of the three states, A, B and E, and the trimer state defined by the triplet of states 
has the effective energy, 
V V V V U U U = + + + + + I II III I/II II/III III/I,
where the intra-energy of the protomer i, Vi, takes one of the three state energies, 
∆V A( = 0), ∆VB and ∆VE , which correspond to the δB and δE respectively, in Figure 2a, 
and Ui/j is the interaction energy between protomers, i and j. The thermodynamic 
probability of the trimer state is written by, as usual, p = exp( − V/T)/Σ exp( − V/T), 
where the sum takes over all the trimer states.
The interaction energy, ∆Uij, was initially estimated by the average energy of 
interface derived from the CG simulation (see Supplementary Fig. S1), and then 
they were calibrated to generate a phase diagram similar to that obtained by the 
simulation (see Supplementary Fig. S6). 
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